|NCPE Assessment process complete
|Treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) (i.e. in the 2nd / 3rd–line treatment setting)
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full Pharmacoeconomic Evaluation Recommended
|Full submission received from Applicant
|NCPE assessment completed
|NCPE assessment outcome
|Reimbursement not recommended. The NCPE do not consider Crizotinib (Xalkori®) a cost-effective treatment for adult patients with previously treated ALK positive advanced non small cell lung cancer (NSCLC).
The HSE has approved reimbursement following confidential price negotiations.